Catalyst Pharmaceuticals, Inc.CPRXNASDAQ
LOADING
|||
Operating Income Growth Under Pressure
Trending lower, below historical average, structural decline.
Left:
||||
Year-over-year operating income growth rate
Latest
-0.05%
↓ 100% below average
Average (39q)
37.27%
Historical baseline
Range
High:1209.49%
Low:-179.63%
CAGR
-14.7%
Structural decline
| Period | Value |
|---|---|
| Q3 2025 | -0.05% |
| Q2 2025 | 4.63% |
| Q1 2025 | 0.83% |
| Q4 2024 | 23.44% |
| Q3 2024 | -6.15% |
| Q2 2024 | 99.98% |
| Q1 2024 | -34.94% |
| Q4 2023 | 212.11% |
| Q3 2023 | -179.63% |
| Q2 2023 | 31.14% |
| Q1 2023 | 15.61% |
| Q4 2022 | 22.70% |
| Q3 2022 | -12.14% |
| Q2 2022 | 64.51% |
| Q1 2022 | 36.29% |
| Q4 2021 | -9.01% |
| Q3 2021 | -11.58% |
| Q2 2021 | 61.60% |
| Q1 2021 | 13.73% |
| Q4 2020 | -26.37% |
| Q3 2020 | 13.83% |
| Q2 2020 | -3.91% |
| Q1 2020 | 33.64% |
| Q4 2019 | -42.17% |
| Q3 2019 | 26.33% |
| Q2 2019 | 1209.49% |
| Q1 2019 | 93.35% |
| Q4 2018 | -81.40% |
| Q3 2018 | -29.15% |
| Q2 2018 | -6.78% |
| Q1 2018 | -7.65% |
| Q4 2017 | -27.98% |
| Q3 2017 | -3.00% |
| Q2 2017 | 10.65% |
| Q1 2017 | -8.48% |
| Q4 2016 | -10.22% |
| Q3 2016 | 18.70% |
| Q2 2016 | 22.81% |
| Q1 2016 | -0.74% |
| Q4 2015 | -23.40% |